| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,595 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
| Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
| Total People Bought |
0 |
1 |
2 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2011-01-26 |
4 |
A |
$0.95 |
$7,917 |
D/D |
8,334 |
2,531,131 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$27,161 |
D/D |
28,895 |
275,243 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$238,741 |
D/D |
253,980 |
2,522,797 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$27,161 |
D/D |
28,895 |
172,983 |
|
- |
|
| Valentine Karen |
Vp and General Counsel |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$18,673 |
D/D |
19,865 |
76,356 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2011-01-20 |
4 |
A |
$0.94 |
$15,703 |
D/D |
16,705 |
88,161 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2011-01-03 |
4 |
A |
$0.95 |
$11,027 |
D/D |
11,607 |
2,268,907 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-12-01 |
4 |
A |
$0.92 |
$11,016 |
D/D |
11,974 |
2,257,300 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-11-01 |
4 |
A |
$0.99 |
$11,000 |
D/D |
11,111 |
2,245,326 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-10-28 |
4 |
AS |
$0.96 |
$1,440 |
D/D |
(1,500) |
166,745 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-10-27 |
4 |
AS |
$0.98 |
$2,450 |
D/D |
(2,500) |
56,491 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2010-10-26 |
4 |
AS |
$0.97 |
$4,040 |
D/D |
(4,165) |
144,088 |
|
- |
|
| Wentworth Kerry |
VP, Clin, Reg & Quality |
• – – |
2010-10-26 |
4 |
A |
$0.98 |
$4,082 |
D/D |
4,165 |
148,253 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-10-26 |
4 |
A |
$0.98 |
$2,450 |
D/D |
2,500 |
58,991 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-10-26 |
4 |
A |
$0.98 |
$3,675 |
D/D |
3,750 |
168,245 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2010-10-26 |
4 |
AS |
$0.97 |
$2,425 |
D/D |
(2,500) |
71,456 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2010-10-26 |
4 |
A |
$0.98 |
$2,450 |
D/D |
2,500 |
73,956 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-10-26 |
4 |
A |
$0.98 |
$8,166 |
D/D |
8,333 |
2,234,215 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-10-01 |
4 |
A |
$0.91 |
$10,976 |
D/D |
12,062 |
2,225,882 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2010-09-30 |
4 |
A |
$0.99 |
$506,927 |
D/D |
512,047 |
2,213,820 |
|
- |
|
| Wentworth Kerry |
Vp, Clin, Reg & Quality |
• – – |
2010-09-14 |
4 |
S |
$0.91 |
$1,315 |
D/D |
(1,453) |
144,088 |
|
- |
|
| Valentine Karen |
VP and General Counsel |
• – – |
2010-09-14 |
4 |
S |
$0.91 |
$3,046 |
D/D |
(3,333) |
56,491 |
|
- |
|
| Sharp Shalini |
CFO |
• – – |
2010-09-14 |
4 |
S |
$0.91 |
$1,824 |
D/D |
(2,000) |
244,098 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2010-09-14 |
4 |
AS |
$0.91 |
$1,239 |
D/D |
(1,365) |
71,456 |
|
- |
|
| Wentworth Kerry |
Vp, Clin, Reg & Quality |
• – – |
2010-09-10 |
4 |
A |
$0.93 |
$4,650 |
D/D |
5,000 |
145,541 |
|
- |
|
535 Records found
|
|
Page 15 of 22 |
|
|
